Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer : Phase II Trial of Dose Dense Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
Upon determination of eligibility, patients will be receive both induction neo-adjuvant regimen and a postoperative adjuvant regimen:Induction Neo-adjuvant: Epirubicin + Gemcitabine + ABI-007 + PegfilgrastimPostoperative Adjuvant: Gemcitabine + ABI-007 + PegfilgrastimUpon completion of chemotherapy, all ER and/or PR+ patients will receive Tamoxifen or an aromatase inhibitor at physician discretion..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
ClinicalTrials.gov - (2021) vom: 23. Nov. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: September 19, 2005, Last downloaded: ClinicalTrials.gov processed this data on December 06, 2021, Last updated: December 08, 2021 |
---|
Study ID: |
NCT00193206 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG000189898 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG000189898 | ||
003 | DE-627 | ||
005 | 20230425204155.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2021 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG000189898 | ||
035 | |a (UBBS_Klinische_Studien)NCT00193206 | ||
035 | |a (UBBS_Klinische_Studien)SCRI BRE 73 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer |b Phase II Trial of Dose Dense Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: September 19, 2005, Last downloaded: ClinicalTrials.gov processed this data on December 06, 2021, Last updated: December 08, 2021 | ||
520 | |a Upon determination of eligibility, patients will be receive both induction neo-adjuvant regimen and a postoperative adjuvant regimen:Induction Neo-adjuvant: Epirubicin + Gemcitabine + ABI-007 + PegfilgrastimPostoperative Adjuvant: Gemcitabine + ABI-007 + PegfilgrastimUpon completion of chemotherapy, all ER and/or PR+ patients will receive Tamoxifen or an aromatase inhibitor at physician discretion. | ||
650 | 2 | |a Breast Neoplasms | |
650 | 2 | |a Inflammatory Breast Neoplasms | |
650 | 4 | |a Medical Condition: Breast Cancer | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Completed | |
650 | 4 | |a Phase: Phase 2 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 23. Nov. |
773 | 1 | 8 | |g year:2021 |g day:23 |g month:11 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT00193206 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 23 |c 11 |